Homepage
Author:
VALNEVA
Posted Date:
May 13, 2026
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
VALNEVA
May 13, 2026
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
VALNEVA
May 5, 2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering
VALNEVA
April 30, 2026
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
VALNEVA
March 26, 2026
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
VALNEVA
March 18, 2026
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
VALNEVA
March 9, 2026
Valneva to Participate in Upcoming Investor Conferences
VALNEVA
March 2, 2026
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
VALNEVA
February 19, 2026
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
VALNEVA
February 13, 2026
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
VALNEVA
February 3, 2026
